Skip to main content
METabolic EXplorer logo

METabolic EXplorer — Investor Relations & Filings

Ticker · METEX ISIN · FR0004177046 LEI · 969500VI1GSBPGD9B460 PA Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2014-12-23 Regulatory Filings
Country FR France
Listing PA METEX

About METabolic EXplorer

https://www.metabolic-explorer.com/

METabolic EXplorer (METEX) is an industrial biotechnology company specializing in the development and industrialization of fermentation bioprocesses. The company produces functional ingredients and chemical intermediates from renewable, non-food raw materials, offering sustainable alternatives to petrochemical processes. Its portfolio is centered on three main product families: 1,3-propanediol (PDO) for cosmetics, liquid polymers, and textiles; butyric acid (BA) for animal nutrition and the flavors and fragrances market; and amino acids for animal feed. The company operates through its subsidiaries, METEX NØØVISTA, which manages the PDO and BA production, and METEX NØØVISTAGO, which focuses on amino acids and ingredients for animal nutrition.

Recent filings

Filing Released Lang Actions
Point sur le programme L-Méthionine à l'étude auprès de la FDA
Regulatory Filings Classification · 95% confidence The document is a press release dated December 23, 2014, providing an update on the status of the L-Methionine program being reviewed by the FDA. It discusses regulatory progress ('dossier a été déposé auprès de la FDA') and expected timelines for feedback. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal presentation (IP). It is a specific, timely communication regarding regulatory/legal progress concerning a product pipeline, which fits best under 'Legal Proceedings Report' (LTR) if it were a lawsuit, but since it is an update on a regulatory filing/approval process, and given the available options, it functions as a general regulatory update or announcement. However, since it is a specific update on a regulatory filing status rather than a general announcement of a report being published (RPA/RNS), and it is not a formal legal proceeding, it is closest to a general regulatory announcement. Given the context of FDA interaction, it is a specific regulatory update. Since there is no specific code for 'Regulatory Update on Product Filing', the closest fit among the specific codes is often 'LTR' for regulatory matters, or 'RNS' as a general regulatory filing fallback. Because it is a direct communication about the status of a regulatory submission (FDA), and not a formal legal proceeding, 'RNS' (Regulatory Filings - general fallback) is the most appropriate category for this type of non-financial, non-meeting specific regulatory news release, unless the document is very short and merely announcing another document, which it is not; it contains substantive information. Given the options, RNS is the best fit for a general regulatory news update that isn't a formal financial report or a specific legal action update.
2014-12-23 French
Chiffre d'affaires au 3ème trimestre 2014
Earnings Release Classification · 98% confidence The document is titled "METabolic EXplorer: Chiffre d'affaires au 3 ème trimestre 2014" (Revenue for the 3rd Quarter 2014) and explicitly states it is publishing its "information financière du 3ème trimestre 2014" (financial information for the 3rd quarter 2014). It provides key financial figures (revenue, cash position) for the period. This content structure—a brief announcement focusing on key results for a specific interim period (Q3)—aligns perfectly with the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). Since it is the initial announcement of period results, ER is the most appropriate classification. Q3 2014
2014-11-14 French
Turnover in third quarter 2014
Interim / Quarterly Report Classification · 95% confidence The document is a press release titled 'Turnover in third quarter 2014' for METabolic EXplorer. It provides specific financial data (turnover and cash position) for the third quarter of 2014, including a table comparing 2013 and 2014 figures. Since it contains substantive financial data for a quarterly period and is not merely an announcement of a report's availability, it qualifies as an Interim/Quarterly Report (IR). Q3 2014
2014-11-14 English
Avancement du projet L-Méthionine
Investor Presentation Classification · 92% confidence The document is a press release dated October 20, 2014, from METabolic EXplorer, providing an update on the progress of its L-Methionine project, discussing market dynamics, scientific advantages of its bio-sourced product over petrochemical alternatives, and upcoming regulatory steps (FDA response expected by year-end 2014). It is not a formal regulatory filing like a 10-K or an IR. It is an update on business and technology progress, which aligns best with an Investor Presentation (IP) or a general business update. Since it details strategy, market analysis, and future steps for investors, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release. It is not a short announcement of a report (RPA/RNS), as it contains substantial detail about the technology and market.
2014-10-20 French
Rapport financier semestriel au 30 juin 2014
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Financier Semestriel' (Interim Financial Report) for the period ending June 30, 2014. It contains comprehensive financial statements, including the balance sheet, income statement, cash flow statement, and statement of changes in equity, as well as management commentary and auditor reports. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year. H2 2014
2014-09-30 French
METabolic EXplorer au 1er semestre 2014 : Partenariat industriel sur le PDO et opportunités de valorisation élargies sur la L-méthionine
Interim / Quarterly Report Classification · 95% confidence The document is a press release from METabolic EXplorer detailing their financial results for the first half of 2014. It includes key highlights, management commentary on business developments (PDO, L-Methionine, MPG), and a summary table of financial results. While it references that a full financial report has been filed with the AMF, the document itself provides substantive financial data and analysis for the interim period. Therefore, it is classified as an Interim/Quarterly Report (IR) rather than a mere announcement (RPA). H1 2014
2014-09-30 French

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.